Back to today’s briefing

Story perspectives

Biotech IPOs Poised for 2026 Resurgence After Slow Year

2/6/2026

44 9 Full Breakdown

Summary

Story summary

In 2025, the biopharma IPO market was slow, with eight companies going public.
Industry experts expect a rebound in IPO activity in 2026.
Eikon Therapeutics raised $381 million in its IPO, the largest biotech IPO since 2024, to fund its lead asset EIK1001 for melanoma and other cancer trials.
AgomAb Therapeutics and SpyGlass Pharma are preparing for IPOs, signaling a potential resurgence in the biotech sector.

1 of 1

Story summary

In 2025, the biopharma IPO market was slow, with eight companies going public.
Industry experts expect a rebound in IPO activity in 2026.
Eikon Therapeutics raised $381 million in its IPO, the largest biotech IPO since 2024, to fund its lead asset EIK1001 for melanoma and other cancer trials.
AgomAb Therapeutics and SpyGlass Pharma are preparing for IPOs, signaling a potential resurgence in the biotech sector.